This study presents the reflections on the role and impact that Dr. Richard F. Bakemeier has had and continues to have on the field of cancer education, the training of medical students, and the careers of cancer educators.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.